Vaccinex (NASDAQ:VCNX – Get Free Report) is projected to release its resultson Monday, August 10th. Analysts expect the company to post earnings of ($73.0380) per share and revenue of $0.05 million for the quarter.
Vaccinex Stock Performance
Shares of VCNX opened at $0.85 on Monday. The business’s 50-day moving average is $1.05 and its two-hundred day moving average is $1.07. The company has a market capitalization of $2.20 million, a P/E ratio of -0.02 and a beta of 1.10. Vaccinex has a fifty-two week low of $0.31 and a fifty-two week high of $1.50.
About Vaccinex
Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.
In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.
Further Reading
- Five stocks we like better than Vaccinex
- 3 Humanoid Robot ETFs to Ride a Speculative Trend
- Bearish Pressure Is Building Around These 3 Stocks
- 3 Low-Volatility Plays Quietly Making a Name For Themselves
- ASML’s Dividend Growth Adds a Quiet Income Angle to Its AI Chip Story
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.
